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See Article, pages 775–781The Hepatitis B e antigen (HBeAg) is a non-particulate secretory
protein, which is not essential for viral assembly or replication
but is important for the establishment of persistent infection
in vivo. A recent study suggested that it down-regulates the
innate immune response to infection and function as a T cell tol-
erogen [1]. For patients with chronic HBeAg positive chronic hep-
atitis B infection (CHB), HBeAg seroconversion, deﬁned as loss of
HBeAg with the appearance of anti-HBe, is often associated with
clinical remission and a transition to inactive liver disease [2].
Accompanying HBeAg seroconversion, there is a reduction in
liver ﬁbrosis, a lower incidence of cirrhosis and hepatocellular
carcinoma. HBeAg seroconversion, whether spontaneous or treat-
ment-induced, is also associated with a higher probability of hep-
atitis B surface antigen (HBsAg) loss and seroconversion, which is
considered to be a more permanent clinical remission of liver
disease. Thus, the achievement and maintenance of HBeAg
seroconversion, in association with polymerase chain reaction-
undetectable hepatitis B virus (HBV) DNA levels, are an important
goal in the management of patients with HBeAg-positive CHB.
Based on evidence demonstrating HBeAg seroconversion as an
important hallmark event of a durable clinical remission of liver
disease, major liver societies treatment guidelines have adopted
HBeAg seroconversion with sustained suppression of HBV DNA
as an end point for treatment in patients with HBeAg-positive
CHB who do not have cirrhosis or decompensated liver disease.
To date, there are seven registered treatments for CHB, two
immunomodulatory agents – conventional interferon-a and
pegylated interferon a2a – and ﬁve nucleos(t)ide analogues
(NUCs) – lamivudine, adefovir dipivoxil, telbivudine, entecavir,
and tenofovir dipropoxil. Among the various forms of treatment,
one-year treatment with pegylated interferon a2a yielded the
highest rate of HBeAg seroconversion (around 40%) and among
them, one-tenth further beneﬁt from HBsAg seroconversion. On
the other hand, treatment with NUCs achieved a much lower rateJournal of Hepatology 20
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ithepa.org (F.-S. Wang).of HBeAg seroconversion and hence more prolonged therapy is
required in CHB patients treated with NUCs. However, with more
prolonged NUCs therapy, the treatment costs escalate and it is
not uncommon, as a practicing clinician, to see patients with pre-
mature termination of NUCs, due to ﬁnancial reasons or non-
compliance. This can result in serious liver-related morbidity
and mortality. It is thus of paramount importance to explore
new treatment methods to hasten and increase the rate of sus-
tained HBeAg seroconversion in chronic HBeAg positive patients
[2].
In order to improve the rate of HBeAg seroconversion, it is
urgently necessary to uncover its underlying mechanisms. In this
aspect, immunological studies on patients before, during, and after
sustained HBeAg seroconversion are of great importance. During
the course of HBeAg seroconversion in CHB patients treated with
antiviral therapy, many important immunological changes have
been observed, reﬂecting the importance of restoration of the host
immunity againstHBV inHBeAg seroconversion. Through compre-
hensive immunological analysis, frequency of plasmacytoid den-
dritic cells (pDCs), Toll-like receptors (TLRs), and programmed
death-1 (PD-1) has been related toHBeAg seroconversion.Notably,
the latter twohave been demonstrated to be regulated by the pres-
ence of HBeAg. These studies have provided some potential immu-
nological biomarkers to predict HBeAg seroconversion [3].
In keeping with the decisive role of cytokines in initiating and
shaping immune-related pathologic responses to chronic viral
infection, interleukin (IL)-10, and IL-12 have been linked to
HBeAg seroconversion. These important ﬁndings were based on
careful analysis of serially collected clinical samples before, dur-
ing and after HBeAg seroconversion in HBeAg-positive CHB
patients. A substantial increase of bioactive IL-12 and Th1 cyto-
kines has been associated with HBeAg seroconversion in
HBeAg-positive CHB patients treated with interferon-a. Impor-
tantly, the peak of IL-12 occurred either before or simultaneously
with hepatitis B e seroconversion [4]. It has also been shown that
higher levels of serum IL-12 and IL-10 were associated with early,
spontaneous HBeAg seroconversion in HBeAg-positive CHB
patients [5].
In this issue of the Journal, Ma et al. explored the role of IL-21
in HBeAg seroconversion. They studied seventy-ﬁve patients with
HBeAg-positive CHB from China who participated in a phase IV,12 vol. 56 j 753–755
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Fig. 1. Immune markers correlate with HBeAg seroconversion. Three stages represent the efﬁcacy of anti-HBV therapy: (1) complete virus suppression (viral load drops
below detectable level) together with ALT normalization. In general, there is a transient or reversible change of enhanced immune response during this period; (2) HBeAg
seroconversion; and (3) HBsAg seroconversion. Immune markers, such as T cell responses, pDC/mDC numbers, Treg numbers, PD-1 expression, IL-12, IL-10, IL-21 are closely
associated with HBeAg seroconversion. However, there are still short of immune markers to predict the HBsAg seroconversion, the ‘‘almost cured’’ clinical status.
Editorialmulti-center, open-label clinical trial of telbivudine
(CLDT600ACN07T). They measured serial serum IL-21 levels by
enzyme linked immunosorbent assay and the proportions of T-
cells producing IL-21 and/or expressing PD-1 in peripheral blood
mononuclear cells, longitudinally during treatment by intracellu-
lar cytokine staining and ﬂow cytometry. They found that serum
IL-21 levels at week 12 of treatment independently predicted
HBeAg seroconversion in the ﬁrst year of treatment. A week 12
serum IL-21 concentration of less than 51.4 pg/ml gave a negative
predictive value for HBeAg seroconversion of 95%. However, the
decreases in PD-1 expression on CD4+ and CD8+ T cells during
the ﬁrst 12 weeks of telbivudine treatment were not correlated
with changes in serum IL-21 levels [6]. In a mouse model, IL-21
has been shown to be an essential component of CD4+ T cell help
for CD8+ T effectors cells in the control of chronic viral infection
[7] and CD4+ T cell help has been shown to play an important role
in restoration of host immune response to CHB. In addition, it has
been shown that IL-21 increases B cell proliferation after activa-
tion via B cell receptor plus T cell derived co-stimulatory signals.
More importantly, IL-21 counteracts the Treg-mediated suppres-
sion of human CD4+ T lymphocytes and regulates the maturation,
growth and cytolytic activity of natural killer (NK) cells and the
proliferation of NKT cells [8]. NK cells are abundant in the liver
and serve as a major innate immune component against micro-
bial infection. Recently, in CHB patients, hepatic NK cells were
found to be activated and preferentially skewed toward cytolytic
activity, which depends on an imbalanced cytokine milieu and
correlates with liver injury during chronic HBV infection. Taking
together, these results explained why week 12 serum IL-21 is
identiﬁed as an immune biomarker for HBeAg seroconversion.
With this important study conducted by Ma et al., more
questions than answers have been raised. Currently, there are
data, though not head-to-head comparison, suggesting a higher
rate of HBeAg seroconversion in HBeAg-positive patients754 Journal of Hepatology 201treated with telbivudine than other NUCs (lamivudine, adefovir
dipivoxil, and entecavir). However, whether this IL-21 increase
is speciﬁc to telbivudine treatment in CHB patients needs to be
understood. Is this enhanced IL-21 level important in inter-
feron-a treated CHB patients? As increased IL-21 can stimulate
host immune response like boosting the T-cell response or B
cell response, it will be of great interest to understand whether
its effect is mediated via immunological changes such as
decrease of PD-1, or Treg or DC.
HBeAg seroconversion confers favorable outcomes together
with signiﬁcant immune alterations in vivo. Due to the versatile
nature of virus-host immune interaction, it is reasonable to spec-
ulate that just measuring one immunological parameter, such as
the frequency or function of a particular immunocyte or the con-
centration of a single cytokine, will not be sufﬁcient to correctly
identify the biomarker of clinical relevance in CHB patients.
Hence, future studies should ﬁgure out a unique panel of immune
biomarkers for the evaluation of the efﬁcacy of the various anti-
HBV therapies and the clinical outcome for CHB patients. Though
HBeAg seroconversion is a critical prerequisite for the clearance
of HBsAg, there is a lack of immune markers to predict the HBsAg
seroconversion (Fig. 1). In particular, no available immune mark-
ers have been found to reﬂect the dynamic alteration of HBsAg
loss together with the appearance of HBsAb in patients with
HBsAg seroconversion. To better optimize antiviral therapy, there
is a call for more translational study. More studies, based on seri-
ally collected clinical samples in well-designed prospective clini-
cal trials, will be required to obtain comparable data and
reference values for surrogate immune markers with relevance
to an ideal treatment end-point (HBsAg seroconversion). In addi-
tion, it is necessary to develop prognostic scores or formulas on
the combination of some immune markers, physiological, and
biochemical indexes to help physicians make decisions on who
should be treated, how to treat, and when to stop treatment.2 vol. 56 j 753–755
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